Guggenheim initiated coverage on Voyager Therapeutics with a new price target
$VYGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Guggenheim initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $22.00